United States Oncolytic Viral Therapy Market Set to Transform Cancer Treatment with Breakthrough Innovations and Rising Global Investments 2025 | Top key players - Amgen, Inc., Daiichi Sankyo Co., Ltd., Lokon Pharma AB.

Market Size and Growth:

The Oncolytic Viral Therapy Market size reached US$ 24.48 Million in 2024 and is expected to reach US$ 164.51 Million by 2033, growing at a CAGR of 23.8% during the forecast period 2025-2033.

The Oncolytic Viral Therapy Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the Oncolytic Viral Therapy market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/oncolytic-viral-therapy-market?sz

The Oncolytic Viral Therapy Market refers to the industry focused on developing and commercializing viruses engineered or naturally occurring to selectively infect and destroy cancer cells while sparing healthy tissues. These therapies stimulate anti-tumor immune responses, offering targeted treatment options. The market encompasses research, clinical trials, regulatory approvals, and commercialization across various cancer types.

Recent Key Developments of United States (U.S):

Clinical Trial Data for Melanoma: On July 18, 2025, a study highlighted the potential of a next-generation oncolytic herpes simplex virus type 1 (RPI) in combination with Opdivo (nivolumab) for advanced melanoma. The trial showed that this combination shrank both injected and non-injected tumors, with a third of patients experiencing a 30% or more reduction in tumor size.

Fast Track Designation: Genelux Corporation's oncolytic virus, Olvi-Vec, received a Fast Track Designation for ovarian cancer. This designation is intended to expedite the development and review of new therapies for serious conditions with an unmet medical need.

Company Financial & Operational Updates: On August 11, 2025, TherivaTM Biologics released its second-quarter 2025 operational highlights and financial results. This included data from its VCN-01 Retinoblastoma Phase 1 clinical trial and a review of topline data from the VIRAGE Phase 2b trial for VCN-01 in metastatic pancreatic cancer.

Clinical Trials for Bladder Cancer: An abstract from the 2025 ASCO Genitourinary Cancers Symposium in February 2025 (published in the last three months) detailed a Phase Ib/II clinical trial of an oncolytic virus (OH2 injection) for preventing recurrence after TURBT in patients with high-risk NMIBC. The data showed promising safety and efficacy signals.

Sarcoma Clinical Trial Results: A Phase 1/2 trial published in January 2025 (within the last three months) demonstrated that intratumoral injection of oncolytic virus OH2 was well-tolerated in patients with locally advanced or metastatic sarcoma, especially when combined with a PD-1 inhibitor (HX008).

Key Players:

Amgen, Inc
Daiichi Sankyo Co., Ltd.
Lokon Pharma AB
Virogin Biotech Canada Ltd
KaliVir Immunotherapeutics, Inc.
Transgene SA
Vyriad, Inc.
Coastar Theapeutics Inc.
IconOVir Bio, Inc.
Calidi Biotherapeutics, Inc.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=oncolytic-viral-therapy-market

Market Segmentation:

By Virus Type: Adenoviruses, Herpes Simplex Virus, Maraba Virus, Measles, Newcastle Disease Virus, Picornavirus, Reovirus, Vaccinia Virus, Vesicular Stomatitis Virus, Others.

By Application: Melanoma, Breast Cancer, Prostate Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Head and Neck Cancer, Others.

By Mode of Administration: Intratumoral Injection, Intravenous Infusion, Intracavitary Injection, Others.

By End-User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Cancer Research Institutes, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/oncolytic-viral-therapy-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Oncolytic Viral Therapy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Oncolytic Viral Therapy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Oncolytic Viral Therapy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Oncolytic Viral Therapy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Oncolytic Viral Therapy Market in 2025?
◆ What is the projected growth rate of the Oncolytic Viral Therapy Market through 2033?
◆ Who are the key players in the Oncolytic Viral Therapy Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.